Clinical trials: Adult Atopic Dermatitis
Dermatitis, Atopic
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis
The purpose of this study is to investigate the safety and efficacy of AN2728 Topical Ointment, 2% in children, adolescents, and adults (ages 2 years and older) with atopic dermatitis.
- Trial name
- NCT02118766
- Testing
- AN2728 Topical Ointment, 2%, Matching vehicle control
- Where
- United States
- Volunteers
- 763 people
- Sponsor
- Pfizer
Atopic Dermatitis
Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis
The purpose of this study is to identify how pimecrolimus cream 1% modifies the molecular and cellular changes associated with the post-lesional phase of atopic dermatitis (AD).
- Trial name
- NCT00117377
- Testing
- Pimecrolimus
- Where
- 3 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Novartis
Atopic Dermatitis (AD), Eczema
Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis
This is a Phase 2a efficacy and safety study of EVO301 for the treatment of adults with atopic dermatitis.
- Conditions
- Atopic Dermatitis (AD), Eczema, Eczema Atopic Dermatitis
- Trial name
- NCT06723405
- Testing
- EVO301
- Where
- 12 sites in Australia, New Zealand
- Volunteers
- 71 people
- Sponsor
- Evommune, Inc.
Healthy Volunteers
A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.
This study consists of 2 parts: Part A is to estimate the relative bioavailability of a single 200 mg dose of abrocitinib oral suspension (Test formulation) compared to the commercial abrocitinib tablet (200 mg) (Reference…
- Trial name
- NCT04903093
- Testing
- Abrocitinib tablet, Abrocitinib Suspension F1, Abrocitinib Suspension F2
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Pfizer
Atopic Dermatitis
HL-300 Ointment in Healthy Volunteers
To evaluate the safety and tolerability of HL-300 ointment following single and multiple topical administrations in healthy Chinese adult volunteers.
- Trial name
- NCT07684937
- Testing
- HL-300
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Atopic Dermatitis
Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7
Primary objective: To demonstrate that tralokinumab in combination with topical corticosteroids (TCS) is superior to placebo in combination with TCS in treating severe AD in subjects who are not adequately controlled with or have…
- Trial name
- ECZTRA 7 (NCT03761537)
- Testing
- Tralokinumab
- Where
- 74 sites in Belgium, Czechia and 5 more
- Volunteers
- 277 people
- Sponsor
- LEO Pharma
Atopic Dermatitis, Atopic
A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.
- Conditions
- Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease
- Trial name
- NCT06436183
- Testing
- Camoteskimab
- Where
- 35 sites in United States, Canada
- Volunteers
- 62 people
- Sponsor
- Apollo Therapeutics Ltd
Atopic Dermatitis
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT05911841
- Testing
- LY3454738
- Where
- 66 sites in United States, Canada and 7 more
- Volunteers
- 234 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis
The objective of this study was to evaluate the safety and efficacy of multiple doses of upadacitinib monotherapy versus placebo in the treatment of adults with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT02925117
- Testing
- Upadacitinib
- Where
- 34 sites in United States, Australia and 6 more
- Volunteers
- 167 people
- Sponsor
- AbbVie
Hidradenitis Suppurativa, Atopic Dermatitis
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
Hidradenitis suppurativa (HS) and atopic dermatitis (AD) are chronic inflammatory skin diseases that lead to the development of skin lesions and symptoms such as pain and discomfort.
- Trial name
- NCT06524635
- Testing
- Lutikizumab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- AbbVie
Pruritus, Atopic Dermatitis
Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
- Trial name
- ATOMIK (NCT02975206)
- Testing
- Serlopitant High Dose, Serlopitant Low Dose
- Where
- 52 sites in United States
- Volunteers
- 484 people
- Sponsor
- Vyne Therapeutics Inc.
Atopic Dermatitis
Frequency of Palpebral Involvement in Adult With Atopic Dermatitis
Atopic dermatitis is a common inflammatory skin disease, resulting from genetical, immunological and environmental factors. Head and neck are among the most frequent involved areas, almost 50% in adult patients according to most…
- Trial name
- PAUPIAD (NCT04826744)
- Testing
- Standard dermatology consultation
- Where
- 2 sites in France
- Volunteers
- 550 people
- Sponsor
- University Hospital, Lille
Atopic Dermatitis
Topical Roflumilast in Adults With Atopic Dermatitis
The purpose of this study is to evaluate the effect of topical roflumilast on the reduction of atopic dermatitis lesions in adults with atopic dermatitis.
- Trial name
- NCT01856764
- Testing
- 0.5% Roflumilast Cream, Vehicle Cream
- Where
- 3 sites in Germany
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Atopic Dermatitis
A Study of MG-K10 in Subjects With Atopic Dermatitis
This study evaluates the preliminary efficacy of MG-K10 in subjects with moderate to severe asthma, and provides a basis for the design and dosing regimen of phase III clinical trials.
- Trial name
- NCT05466877
- Testing
- MG-K10
- Where
- 2 sites in China
- Volunteers
- 163 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Atopic Dermatitis
Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndrome
To demonstrate the superiority of IMP (1% OPA-15406 ointment or vehicle) to the vehicle when administered twice daily for 4 weeks using success rate in Investigator's Global Assessment (IGA) at Week 4 as the primary endpoint in…
- Trial name
- NCT03908970
- Testing
- 1% OPA-15406
- Where
- Japan
- Volunteers
- 364 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Dermatitis, Atopic
Protopic Ointment in Adult Atopic Eczema of the Face
Patients with facial atopic eczema and a poor response to topical corticosteroid applied either Protopic or Fluticasone ointment twice a day for 3 weeks.
- Trial name
- NCT00690105
- Testing
- tacrolimus 0.1%, fluticasone 0.005 %
- Where
- France
- Volunteers
- 577 people
- Sponsor
- Astellas Pharma Inc
Dermatitis, Atopic, Pruritus
A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis
The goal of this clinical trial is to evaluate ASN008 in people with itch caused by eczema. The main questions it aims to answer are: What is the efficacy and safety of ASN008? What is the impact of ASN008 on itch in patients…
- Trial name
- NCT05870865
- Testing
- ASN008, ASN008 Matching Vehicle
- Where
- 27 sites in United States
- Volunteers
- 144 people
- Sponsor
- Formation Bio, Inc.
Atopic Dermatitis
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
- Trial name
- ROCKET-ASCEND (NCT05882877)
- Testing
- Rocatinlimab
- Where
- 547 sites in United States, Argentina and 40 more
- Volunteers
- 2,621 people
- Sponsor
- Amgen
Atopic Dermatitis
A Study to Assess Change in Disease Activity in Adolescents and Adults With Moderate to Severe Prurigo-type Atopic Dermatitis in Japan Who Are Treated With Oral Upadacitinib
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Around one-third of patients with AD have had at least 1 incidence of prurigo nodularis (PN), which is characterized by…
- Trial name
- ADMIRE (NCT05451316)
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- AbbVie
Atopic Dermatitis
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and…
- Trial name
- TRuE-AD4 (NCT06238817)
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 94 sites in United States, Australia and 12 more
- Volunteers
- 241 people
- Sponsor
- Incyte Corporation